Do you or someone you know have Castleman disease?

The Castleman Disease Collaborative Network (CDCN) is working on a very important research study

The CDCN has partnered with the University of Pennsylvania and the University of Arkansas for Medical Sciences to conduct a research study of an investigational medicine for individuals between the ages of 18 and 80 who have idiopathic multicentric Castleman disease (iMCD) and are unable to benefit from anti-IL-6 therapies. Anti-IL-6 therapies are siltuximab (Sylvant) and tocilizumab (Actemra). If you are an iMCD patient who is currently experiencing disease activity and are either unable to tolerate anti-IL-6 therapy, or your disease does not respond to anti-IL-6 therapy, please contact the CDCN for additional information on this study. Participation in this study is entirely voluntary.

Eligible participant will receive, at no cost, study related:

- Medical procedures
- Laboratory assessment
- Investigational medication
- Reimbursement for study travel may be available

If you are interested in participating or have any questions about this study, please contact research staff:

Call: Marita Lynch @ (215) 615-0310
Email: CDTrial@PennMedicine.UPenn.edu